title: Modifying effects of anticancer drugs adriamycin, actinomycin D, and cisplatin on N-2-fluorenylacetamide-induced hepatocarcinogenesis in male ACI/N rats.
abstract: The effects of some well-known anticancer agents, adriamycin (ADR), actinomycin D (ACT), and cisplatin (CIS), on hepatocarcinogenesis induced by N-2-fluorenylacetamide (FAA) were examined in male ACI/N rats. Animals were divided into 15 groups and treated as follows: group 1, 0.02% FAA diet (13 wk); group 2, FAA diet and 0.05% phenobarbital (PB) diet (16 wk); group 3, FAA diet and ADR (3 ip injections of 1.00 mg/kg body weight/wk); group 4, FAA, ADR, and PB; group 5, FAA and ACT (3 ip injections of 0.02 mg/kg body weight/wk); group 6, FAA, ACT, and PB; group 7, FAA and CIS (3 ip injections of 1.00 mg/kg body weight/wk); group 8, FAA, CIS, and PB; group 9, ADR; group 10, ADR and PB; group 11, ACT; group 12, ACT and PB; group 13, CIS; group 14, CIS and PB; group 15, nontreatment. At the end of the experiment (30 wk), the incidence of preneoplastic and neoplastic hepatocellular lesions was evaluated. All three tested compounds, especially CIS, inhibited the development of preneoplastic and neoplastic liver lesions, indicating CIS could be valuable as a therapeutic agent for hepatocellular malignancies.
authors.affiliation: 1st Department of Pathology, Gifu University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Takeuchi
authors.forename: M
authors.initials: M
authors.lastname: Shimizu
authors.forename: Y
authors.initials: Y
authors.lastname: Morishita
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: H
authors.initials: H
authors.lastname: Mori
mesh_terms: D015073:2-Acetylaminofluorene; D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003609:Dactinomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011912:Rats, Inbred ACI
chemical_list: D003609:Dactinomycin; D004317:Doxorubicin; D015073:2-Acetylaminofluorene; D002945:Cisplatin